Oppenheimer Maintains Outperform on Ionis Pharmaceuticals, Raises Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson maintains an Outperform rating on Ionis Pharmaceuticals (NASDAQ:IONS) and raises the price target from $65 to $72.
March 06, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson maintains an Outperform rating on Ionis Pharmaceuticals and raises the price target from $65 to $72.
The increase in the price target by a reputable analyst suggests a positive outlook on the stock, likely leading to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100